Comment from Novartis Pharmaceuticals Corp.

Summary: Novartis Pharmaceuticals Corp. supports the FDA's initiative to explore AI-enabled real-time clinical trial data submissions to improve drug development efficiency. They recommend focusing the pilot on identifying use cases that reduce pauses between development phases, such as improving patient recruitment and speeding up transitions between dosing cohorts.